Kevin Patrick Danahy Sells 20,000 Shares of Pulse Biosciences (NASDAQ:PLSE) Stock

Key Points

• Kevin Patrick Danahy sold 20,000 shares of Pulse Biosciences stock for a total of $369,800, resulting in a 31.60% decrease in his ownership of the company.
• Pulse Biosciences shares traded down 0.3% to $17.56, with a 1-year low of $13.77 and a high of $25.00.
• Oppenheimer has assigned an "outperform" rating to Pulse Biosciences with a target price of $22.00, highlighting a generally positive outlook among analysts.

Pulse Biosciences, Inc (NASDAQ:PLSE - Get Free Report) insider Kevin Patrick Danahy sold 20,000 shares of the company's stock in a transaction that occurred on Thursday, September 18th. The shares were sold at an average price of $18.49, for a total value of $369,800.00. Following the completion of the transaction, the insider directly owned 43,298 shares of the company's stock, valued at $800,580.02. This trade represents a 31.60% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Kevin Patrick Danahy also recently made the following trade(s):

• On Friday, September 19th, Kevin Patrick Danahy sold 400 shares of Pulse Biosciences stock. The shares were sold at an average price of $18.48, for a total value of $7,392.00.

Pulse Biosciences Trading Down 0.3%

Shares of NASDAQ PLSE traded down $0.05 during midday trading on Monday, reaching $17.56. 264,478 shares of the company were exchanged, compared to its average volume of 222,876. Pulse Biosciences, Inc has a 1 year low of $13.77 and a 1 year high of $25.00. The stock has a market cap of $1.18 billion, a P/E ratio of -16.72 and a beta of 1.68. The stock has a fifty day simple moving average of $15.60 and a 200 day simple moving average of $16.14.

Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.02).

Analyst Upgrades and Downgrades

Separately, Oppenheimer assumed coverage on shares of Pulse Biosciences in a report on Monday, July 7th. They issued an "outperform" rating and a $22.00 target price for the company. One analyst has rated the stock with a Buy rating, According to MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $22.00.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Nuveen LLC acquired a new position in Pulse Biosciences in the first quarter valued at $915,000. Pandora Wealth Inc. acquired a new position in shares of Pulse Biosciences during the 1st quarter valued at about $828,000. Geode Capital Management LLC lifted its holdings in shares of Pulse Biosciences by 7.2% during the 2nd quarter. Geode Capital Management LLC now owns 499,464 shares of the company's stock worth $7,538,000 after acquiring an additional 33,744 shares during the period. XTX Topco Ltd acquired a new stake in shares of Pulse Biosciences in the second quarter worth approximately $466,000. Finally, Quadrature Capital Ltd acquired a new position in Pulse Biosciences during the second quarter worth approximately $388,000. 76.95% of the stock is currently owned by institutional investors and hedge funds.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.